GlassScriptPhysician profile
Nayvi Serrano
NPI 1043677024
$2,217.55
in general payments reported to CMS, 2019-2025
27 companies · $261 in 2025
The $261 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,015 · 2022: $739 · 2023: $23.95 · 2024: $178 · 2025: $261.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $463.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $463.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $235.45 | 2021-2023 | Ztlido |
| Almatica Pharma LLC | $222.20 | 2021-2022 | |
| Forte Bio-Pharma LLC | $193.56 | 2021 | |
| Daiichi Sankyo INC. | $183.93 | 2024-2025 | Datroway, Enhertu |
| Virtus Pharmaceuticals LLC | $167.13 | 2021 | |
| Horizon Therapeutics Plc | $115.78 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $101.77 | 2024-2025 | Enhertu, Tagrisso, Lynparza |
| Biohaven Pharmaceutical Holding Company LTD. | $99.77 | 2022 | |
| Collegium Pharmaceutical, INC. | $94.24 | 2021 | |
| Grt US Holding, INC. | $78.22 | 2022 | |
| Novartis Pharmaceuticals Corporation | $77.96 | 2021-2025 | |
| Boston Scientific Corporation | $63.49 | 2021-2022 | |
| Redhill Biopharma INC. | $63.26 | 2021-2022 | |
| Nalu Medical, INC. | $51.60 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $49.71 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hikma Pharmaceuticals USA | $47.95 | 2022 | |
| Spr Therapeutics, INC | $47.93 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.73 | 2021 | |
| Janssen Biotech, INC. | $45.62 | 2025 | Darzalex, Tecvayli, Akeega |
| Merz Pharmaceuticals, LLC | $43.44 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $42.24 | 2022 | |
| Bioprotect Medical, INC. | $36.58 | 2025 | Bioprotect Balloon Implant System |
| Abbvie INC. | $28.22 | 2021-2022 | |
| Medtronic, INC. | $23.32 | 2021 | |
| Lilly USA, LLC | $20.00 | 2021 | |
| Biodelivery Sciences International, INC. | $19.19 | 2021 | |
| Incyte Corporation | $17.26 | 2025 | Niktimvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nayvi Serrano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.